



# 28th Annual Heart Failure 2024

*An Update on Therapy*

April 20, 2024

Millennium Biltmore Hotel in Los Angeles, CA

Program Director

Uri Elkayam, MD, FACC, FAHA, FHFSA

Program Co-Director

Anil K. Bhandari, MD, FACC, FHRS



*Supported by*

PIH Health Good Samaritan Hospital  
Los Angeles, CA

*Officially Endorsed by*




*Hybrid Event - Attend In-person or Online*



**LAHeartFailure.com**

# COURSE DESCRIPTION

**T**he 28th Annual Heart Failure 2024 - An Update on Therapy Symposium continues the tradition of providing a comprehensive update on the prevention, diagnosis, and management of heart failure. The program includes lectures presented by experts combined with an opportunity for interactive discussion with faculty. The extensive list of topics has been selected to provide a contemporary, high level and clinically relevant update with a goal of improving clinicians' knowledge and the care of patients with heart failure of various etiologies. This year we are offering a Hybrid Event - Attend In-person or Virtually.



## PROGRAM OBJECTIVES:

At the conclusion of this activity, the participants should be able to:

1. To review the appropriate use of guidelines directed medical therapy for patients with chronic heart failure with reduced and preserved ejection fraction.
2. To discuss the management of hospitalized patients with acute decompensated heart failure.
3. To provide an update on the use of catheter based interventions for the management of patients with heart failure due to valvular heart disease.

## TARGET AUDIENCE

This program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.

# NEEDS ASSESSMENT



**C**urrent estimates are that nearly 6.5 million Americans over the age of 20 have heart failure (HF) and there are 960,000 new cases annually. HF is one of the most common causes of cardiovascular mortality and severe morbidity. Recently developed and approved drugs and devices for the management of heart failure provide a great opportunity for improved outcome and need to be incorporated into the care of patients with heart failure. Recent data continues to show an important gap between published guideline recommendations for diagnosis and treatment of heart failure and practice (Journal of clinical medicine 2023; 12:1020) and demonstrates that life-saving drugs and devices are underutilized. Inadequate guideline directed medical therapy (GDMT) has been shown to confer a significant excess mortality (Clin Cardiol. 2021; 44:1192–1198). Most patients with HF are managed by non-cardiologist health care providers and providers without training in advanced heart failure (Int J Cardiol 2021; 343:63). Physicians' education has been shown to result in a significant improvement in knowledge scales in HF care. (PLoS One 2022 Feb 4;17(2): e0263523). Non-surgical, catheter-based repair of different valves is available to patients with heart failure who are at high risk for surgery. There is still underutilization of these procedures. (Cardiovasc Revasc Med 2022; 37:712) For all these reasons there is a need for education and incorporation of recent guidelines by clinicians. The 2024 symposium continues the tradition of almost 3 decades and has been designed to provide a comprehensive update on many of the new diagnostic and therapeutic modalities as well as information on new practice guidelines for the management of patients with HF.

## ACCREDITATION

The AAFP has reviewed **28th Annual Heart Failure 2024: An Update on Therapy** and deemed it acceptable for up to **6.0** Live AAFP Prescribed credits. Term of Approval is from 04/20/2024 to 04/20/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to **AMA PRA Category 1 credit(s)**™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

## FACULTY DISCLOSURE

It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual's control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker's outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

# FACULTY

## Program Director



### **Uri Elkayam, MD, FACC**

Professor of Medicine, Division of Cardiology  
University of Southern California  
Keck School of Medicine  
Los Angeles, CA

## Program Co-Director



### **Anil K. Bhandari, MD, FACC, FHRS**

Chief, Division of Cardiology  
Director, Electrophysiology Services  
Director, GME and CME Committee  
PIH Health Good Samaritan Hospital  
Los Angeles, CA  
Clinical Professor of Medicine  
Keck School of Medicine of University of  
Southern California  
Los Angeles, CA

## Guest Faculty



### **Ulrika Birgersdotter-Green, MD**

Director, Pacemaker and ICD Services  
Professor of Medicine  
UC San Diego  
La Jolla, CA



### **Steven Burstein, MD, FACC**

Director, Interventional Cardiology  
Director, Structural Heart Program  
PIH Health Good Samaritan Hospital  
Los Angeles, CA



### **Leslie Cooper, Jr., MD, FACC, FAHA**

Chair, Cardiovascular Medicine, Florida  
Elizabeth C. Lane, Ph.D. and  
M. Nadine Zimmerman, Ph.D. Professor of Inter-  
nal Medicine  
Mayo Clinic  
Jacksonville, Florida | Rochester, Minnesota



### **Gregg Fonarow, MD, FACC, FAHA, HFSA**

Eliot Corday Professor of  
Cardiovascular Medicine and Science  
Director, Ahmanson - UCLA Cardiomyopathy Center  
Co-Director, UCLA Preventative  
Cardiology Program  
Interim Chief, UCLA Division of Cardiology  
David Geffen School of Medicine  
Los Angeles, CA



### **Barry H. Greenberg, MD, FACC**

Distinguished Professor of Medicine  
Department of Medicine/Cardiology  
UC San Diego  
La Jolla, CA



### **Saibal Kar, MD, FACC, FSCAI**

Director of Structural Heart Disease  
Interventions and Clinical Research at  
Los Robles Health System  
Physician Director of Interventional Cardiology-  
Hospital Corporation of America/HCA  
Los Robles Regional Medical Center  
Thousand Oaks, CA



### **Tien Ng, PharmD, HFSA, FCCP, BCPS, FACC**

Interim Chair & Professor of the  
Titus Family Department of Clinical Pharmacy  
USC Alfred E. Mann School of Pharmacy and  
Pharmaceutical Sciences  
Los Angeles, CA



### **Milton Packer, MD**

Distinguished Scholar in Cardiovascular Science  
Baylor University Medical Center  
Dallas, TX  
Visiting Professor at Imperial College  
London, UK



### **Ileana L. Piña, MD, MPH, FAHA, FACC**

Professor of Medicine  
Thomas Jefferson University  
Quality Chief for the CV Line  
Philadelphia, PA



### **Nir Uriel, MD, MSc, FACC**

Professor of Medicine  
Seymour, Paul, and Gloria Milstein Professor of  
Cardiology (In Medicine)  
Director of NYP Heart Failure, Cardiac Transplantation, and  
Mechanical Circulatory Support  
Columbia University Irving Medical Center  
Weill Cornell Medicine  
New York, NY



### **Brandon M. Wiley, MD, FASE, FACC, FCCM**

Director of Cardiac Intensive Care Unit  
Chief of Cardiology  
LAC+USC Medical Center  
Associate Professor of Medicine  
Keck School of Medicine of USC  
Los Angeles, CA



### **Clyde W. Yancy, MD, MSc, FMACC, FAHA, MACP, HFSA, FRCP**

Vice Dean, Diversity & Inclusion  
Magerstadt Professor of Medicine  
Professor of Medical Social Sciences  
Chief, Division of Cardiology  
Northwestern University  
Chicago, IL

# PROGRAM

## Saturday, April 20, 2024

7:00-8:00am Registration/Visit Exhibits

8:00-9:00 **Product Theatre I - Breakfast** - Non-CME

**Changing the Treatment Paradigm in Recurrent Pericarditis (RP):  
Moving Beyond an Episodic Approach**

Dor Lotan, MD

*Supported by: Kiniksa*

9:00-9:15 **Introduction to the 28th Annual Symposium:**

**Heart Failure 2024 - An Update on Therapy**

Uri Elkayam, MD

### SESSION I

9:15-9:35 **The Use Of GDMT In Patients With Heart Failure -When And How To Do It?**  
Clyde Yancy, MD

9:35-9:55 **SGLT2 Inhibitors In Heart Failure: Mechanism Of Action And the Use  
Across The Ejection Fraction Spectrum**  
Milton Packer, MD

9:55-10:15 **Sotagliflozin, A New Therapeutic Option For the Treatment of Heart Failure**  
Tien Ng, PharmD

10:15-10:35 **Contemporary Therapy Of Heart Failure And Preserved Ejection  
Fraction (HFpEF)-Drugs And Devices**  
Barry Greenberg, MD

10:35-10:50 *Visit Exhibits/Break*

### SESSION II

10:50-11:10 **New Therapeutic Options For The Management Of The Hospitalized  
Patients With Decompensated Heart Failure**  
Uri Elkayam, MD

11:10-11:30 **Iron Supplement For Patients With Heart Failure – What Is The Evidence?**  
Ileana Pina, MD

11:30-11:50 **Hospital At Home As A Treatment Strategy For Worsening Heart Failure**  
Gregg Fonarow, MD

11:50-12:10 **Cardiac Sarcoidosis: Diagnosis, Prognosis And Management**  
Leslie Cooper, Jr., MD

12:10-1:20 **Product Theatre II - Luncheon** - Non-CME  
**Wainua: Overview of a Treatment Option for hATTR-PN**  
Ted Okerson, MD  
*Supported by: AstraZeneca*

1:20-1:35 *Visit Exhibits/Break*

*program continued on following page*

# PROGRAM

---

## *Saturday Continued*

### **SESSION III**

- 1:35-2:05      **KEYNOTE LECTURE**  
**The Future Of Heart Failure**  
Milton Packer, MD
- 2:05-2:25      **The Cardiogenic Shock Team**  
Brandon Wiley, MD
- 2:25-2:45      **The Hemodynamic Renaissance: Value Of Hemodynamic Guided Management Of Patients With Heart Failure**  
Nir Uriel, MD
- 2:45-3:05      **Peripartum Cardiomyopathy: Recovery Or Remission?**  
Uri Elkayam, MD
- 3:05-3:20      *Visit Exhibits/Break*

### **SESSION IV**

- 3:20-3:40      **Left Bundle Branch Pacing Versus Biventricular Pacing For Cardiac Resynchronization**  
Ulrika Birgersdotter-Green, MD
- 3:40-4:00      **Advances In Atrial Fibrillation Ablation In Patients With Heart Failure**  
Anil Bhandari, MD
- 4:00-4:20      **Trans Catheter Repair Of Functional Mitral Regurgitation: Long Term Results And Patient Selection**  
Steve Burstein, MD
- 4:20-4:40      **Nonsurgical Tricuspid Valve Repair: A Status Report**  
Saibal Kar, MD
- 4:40-4:55      **Closing Remarks**  
Uri Elkayam, MD



# COURSE LOCATION & INFORMATION

## MILLENNIUM BILTMORE HOTEL

506 South Grand Avenue  
Los Angeles, CA 90071  
(213) 624-1011

### Special Group Rate Available until March 20:

A limited number of guest rooms are available for a rate of \$TBD Single/Double plus occupancy tax of 16% and overnight parking. Reservations must be guaranteed by a major credit card. Cancellations without penalty must be made 36 hours prior to your arrival. **Call the hotel directly Mon-Fri 9am- 5pm (213-612-1575) to book reservations directly (mention the Heart Failure Symposium). For online reservations use hotel link on the symposium website (symposium registration also available).**

**Register at: [LAHeartFailure.com](https://LAHeartFailure.com)**

## PARKING

Valet event parking at the hotel is \$30 for the day. Valet parking at the hotel for overnight guests is \$65. Self parking is available on Saturday at the Pershing Square Garage for \$9 (until 2:00am), overnight parking is \$20 (24hrs). - *subject to change.*

## CANCELLATIONS

Because of advance planning requirements, a full refund less a \$50.00 processing fee will be given if you cancel in writing and postmark by **March 29, 2024**. No refunds will be given after March 29, 2024.

## CONFERENCE SECRETARIAT

### Complete Conference Management

3320 Third Avenue, Suite C  
San Diego, CA 92103 Ph. 619-299-6673

## REGISTRATION FEES

	Early Bird on or before Feb. 20, 2024	Pre-Registration Feb. 21 - Apr. 4, 2024	On-site Registration After Apr. 4, 2024
Physician	\$130	\$150	\$160
Nurse / Allied Health	\$100	\$120	\$130
Student/Fellow (with letter of verification)	\$50	\$50	\$50

Registration includes morning coffee, lunch, coffee breaks, online syllabus & online CME certificate. Confirmation and directions will be sent by email. **Pre-registration with payment is required to secure lower tuition rate. Please enroll early - registration is limited. Register online at: [LAHeartFailure.com](https://LAHeartFailure.com)**  
**Symposium will not refund travel costs in the event of a course cancellation.**

## REGISTRATION FORM

Attending: ☐ In-Person ☐ Virtually

Name \_\_\_\_\_  
Last First MI Title

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Phone ( ) \_\_\_\_\_ Email \_\_\_\_\_

Professional Specialty \_\_\_\_\_ Special Needs for Disabled \_\_\_\_\_

Please indicate Optional Sessions if attending in-person (RSVP Requested):

☐

Breakfast Session

☐

Lunch Session

## CHECK PAYMENT

Make your check or money order payable to:

**Foundation for Heart  
Failure Education, Inc.**

## MAIL FORM TO:

Complete Conference Management  
3320 Third Avenue, Suite C  
San Diego, CA 92103

## FAX TO:

619-299-6675

CREDIT CARD PAYMENT – (Visa, Mastercard, American Express and Discover **ONLY**)

Card # \_\_\_\_\_ Security Code \_\_\_\_\_

Name on Card \_\_\_\_\_ Exp. Date \_\_\_\_\_

Billing Address \_\_\_\_\_

Amount \$ \_\_\_\_\_ Signature \_\_\_\_\_